Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Rallybio Corporation (RLYB : NSDQ)

• Company Description    Rallybio Corporation is a clinical-stage biotechnology company committed to identifying and accelerating the development of therapies for patients with severe and rare diseases. Rallybio Corporation is headquartered in New Haven, Connecticut. Number of Employees: 35

• Price / Volume Information    Yesterday's Closing Price: $9.82 Daily Weekly Monthly 20 Day Moving Average: 44,843 shares Shares Outstanding: 32.13 (millions) Market Capitalization: $315.53 (millions) Beta: 52 Week High: $25.78 52 Week Low: $6.74 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -6.83% 4.94% 12 Week -12.94% -4.29% Year To Date 2.93% 25.77%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 234 CHURCH STREET SUITE 1020 - NEW HAVEN,CT 06510 USA ph: 203-859-3820 fax: - investors@rallybio.com http://www.rallybio.com

• General Corporate Information    Officers Martin W. Mackay - Chief Executive Officer and Director Jeffrey M. Fryer - Chief Financial Officer and Treasurer Helen M. Boudreau - Director Rob Hopfner - Director Ronald M. Hunt - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 75120L100 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/22 Next Expected EPS Date: 09/08/22 Share - Related Items Shares Outstanding: 32.13 Most Recent Split Date: (:1) Beta: Market Capitalization: $315.53 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.61 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-2.16 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 09/08/22

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.94 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -% vs. Previous Quarter: -14.29% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 03/31/22 - -42.33 12/31/21 - -64.24 09/30/21 - - ROA 03/31/22 - -28.99 12/31/21 - -37.90 09/30/21 - - Current Ratio 03/31/22 - 28.93 12/31/21 - 27.61 09/30/21 - 26.20 Quick Ratio 03/31/22 - 28.93 12/31/21 - 27.61 09/30/21 - 26.20 Operating Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Net Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Pre-Tax Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Book Value 03/31/22 - 5.07 12/31/21 - 5.47 09/30/21 - 5.80 Inventory Turnover 03/31/22 - - 12/31/21 - - 09/30/21 - - Debt-to-Equity 03/31/22 - 0.00 12/31/21 - 0.00 09/30/21 - 0.00 Debt-to-Capital 03/31/22 - 0.00 12/31/21 - 0.00 09/30/21 - 0.00

Powered by Zacks Investment Research ©